C Diff Drug Development

Manipulation of the gut microbiota via fecal microbiota transplantation (FMT) has shown clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI). However, the variable nature of this approach makes it challenging to describe the relationship between fecal strain colon …

The ability of the anaerobic gastrointestinal pathogen Clostridioides difficile to survive outside the host relies on the formation of dormant endospores. Spore formation is contingent on the activation of a conserved transcription factor, Spo0A, by phosphorylation. Multiple kinases and phosphatases …

Researchers at Harvard University and the Massachusetts Institute of Technology have created a type of bacteria that could potentially protect humans from the harmful side effects of antibiotics, according to a new study published in the journal Nature Biomedical Engineering.

BOSTON, April 13, 2022--PureTech Founded Entity Vedanta Biosciences announced the publication in the journal Cell Host & Microbe of the results from a study for VE303

/PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines targeting chronic inflammatory diseases, today...

Antibiotic-induced alterations in the gut microbiota are implicated in many metabolic and inflammatory diseases, increase the risk of secondary infections and contribute to the emergence of antimicrobial resistance. Here we report the design and in vivo performance of an engineered strain of Lactoco …

Clostridioides difficile bacteria can cause life-threatening diarrhea and colitis owing to limited treatment options and unacceptably high recurrence rates among infected patients. This necessitates the development of alternative routes for C. difficile treatment. Drug repurposing with new indicatio …

Spirulina has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments, say US developers.

Manchmal begünstigen Antibiotika die Entstehung einer potenziell tödlichen Durchfallerkrankung. Statt die verursachenden Keime mit weiteren Antibiotika zu töten, haben Ärzte einen anderen Weg gefunden, die Übeltäter in Schach zu halten.

Learn about our technology, resources, and clinician & patient participation in clinical trials.

The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada The extension of the clinical...

A month after another setback in its plans to treat ulcerative colitis, Seres Therapeutics quietly disclosed it will not move forward with a Phase Ib trial. The move, disclosed in an SEC filing Wednesday, puts Seres in a predicament as the Cambridge, MA biotech failed with one potential UC drug,

Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to evaluate the safety, efficacy, and durability of RBX2660—a standardized microbiota-based investigational live biotherapeutic—and a closely-matched historical control cohort. Methods This prospective, multicenter, open-label Phase 2 study enrolled patients who had experienced either ≥ 2 recurrences of CDI, treated by standard-of-care antibiotic therapy, after a primary CDI episode, or ≥ 2 episodes of severe CDI requiring hospitalization. Participants received up to 2 doses of RBX2660 rectally administered with doses 7 days apart. Treatment success was defined as the absence of CDI diarrhea without the need for retreatment for 8 weeks after completing study treatment. A historical control group with matched inclusion and exclusion criteria was identified from a retrospective chart review of participants treated with standard-of-care antibiotics for recurrent CDI who matched key criteria for the study. The primary objective was to compare treatment success of RBX2660 to the historical control group. A key secondary outcome was the safety profile of RBX2660, including adverse events and CDI occurrence through 24 months after treatment. In addition, fecal samples from RBX2660-treated participants were sequenced to evaluate microbiome composition and functional changes from before to after treatment. Results In this Phase 2 open-label clinical trial, RBX2660 demonstrated a 78.9% (112/142) treatment success rate compared to a 30.7% (23/75) for the historical control group (p

Our findings do not suggest CI proteins CI_01448 and CI_01447, which cross-react with antibodies against CD toxins A and B, are toxic to HeLa cells. Further studies are needed to determine the function of these cross-reacting proteins and the potential virulence factors that could be responsible for …

Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. | Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. With its lead program under clinical hold, the microbiome specialist has pulled out of a planned study in chronic hepatitis B.

/PRNewswire/ -- Morningside Ventures today announced the launch of Adiso Therapeutics, a clinical-stage biotechnology company advancing a pipeline of novel...

While physicians express excitement surrounding products in the microbiome sector, current challenges with access to fecal microbiota transplants may translate into slow adoption EXTON, Pa., March 23, 2022 /PRNewswire/

DNV3837 Drug Trial update

RBX2660, a standardized, stabilized, novel microbiota-based live therapeutic, shows promise treating patients with recurrent Clostridium difficile infection.

A new report from an industry association showed an increase in development from small companies, but funds remain limited.

Nearly 8 in 10 patients with recurrent C. diff. Infection were successfully treated after up to 2 doses of the microbiota-based therapy.

A new report on the recurrent #Cdiff infection therapy RBX2660 from @ferring suggests the microbiome benefits of the therapy can last up to 2 years #IDtwitterhttps://t.co/ZrFCIBlyOF— Contagion (@Contagion_Live) March 22, 2022

Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3

Seres Therapeutics, Inc. will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting.

Pfizer’s investigational C. diff vaccine was shown to reduce the duration and severity of disease, but not prevent primary C. diff infection.

In this Phase 2 trial, RBX2660 was safe and effective for reducing rCDI recurrence as compared to a historical control group. Microbiome changes are consistent with restorative changes implicated in resisting C. difficile recurrence. Clinical Trials Registration NCT02589847 (10/28/2015).